Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2026-05-27 Director's Dealing
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Dr. Olaf Stiller, buy
Director's Dealing Classification · 98% confidence The document is a public notification of share transactions by a person in a management position (Dr. Olaf Stiller), detailing date, volume, price, and instrument ISIN. This matches the Director’s Dealing category for insider trades by directors.Therefore, the appropriate classification is DIRS.
2026-05-27 German
NanoRepro AG: Dr. Olaf Stiller, buy
Director's Dealing Classification · 92% confidence The document is a mandatory public disclosure detailing an insider transaction: it reports the purchase of shares by Dr. Olaf Stiller (a member of the supervisory board) in NanoRepro AG, including instrument type (share), ISIN, volume, price, trade date, and venue. This matches the definition for Director's Dealing (Code: DIRS).
2026-05-26 German
NanoRepro AG: Dr. Olaf Stiller, buy
Director's Dealing Classification · 95% confidence The document is a notification of insider transactions by Dr. Olaf Stiller (a member of the supervisory board) purchasing shares of the company, detailing transaction dates, volumes, prices, and ISIN. This matches the definition of Director's Dealing (insider share transactions by executives).
2026-05-25 German
NanoRepro AG: Beteiligungen als Wachstumsmotor im Geschaftsjahr 2025 Strategische Fokussierung schafft Grundlage fur profitables Wachstum
Earnings Release Classification · 87% confidence The document is a corporate news/financial press release issued via EQS News on April 22, 2026. It provides a high‐level summary of preliminary full‐year 2025 financial results (revenues, strategic highlights, outlook) rather than the complete annual report. This matches the definition of an Earnings Release (initial announcement of periodical financial results). FY 2025
2026-04-22 German
NanoRepro AG: Neues Vorstandsmitglied und Einleitung eines strategischen Reviewprozesses Die Transformation nimmt Fahrt auf
Board/Management Information Classification · 87% confidence The document is a corporate press release announcing the appointment of a new board member (Vorstandsmitglied) and the departure of a prior member, along with an organizational strategic review. It clearly falls under announcements of changes in the company's board or senior management, matching the Board/Management Information category.
2026-04-02 German
NanoRepro AG beschliet Barkapitalerhohung mit Bezugsrechtsausschluss aus genehmigtem Kapital im Umfang von bis zu 10% des Grundkapitals
Capital/Financing Update Classification · 100% confidence The document is an official ad-hoc announcement (insider information) regarding a capital increase (Barkapitalerhöhung) by NanoRepro AG. It details the issuance of new shares, the exclusion of subscription rights, and the intended use of proceeds. This falls under the category of capital structure changes and financing activities, which is classified as CAP.
2026-02-24 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.